9 September 2024
Avacta Group
plc
("Avacta"
or "the Group" or "the Company")
Avacta to present updated
clinical data on AVA6000 at the European Society for Medical
Oncology (ESMO) Congress
Avacta Group plc (AIM: AVCT), a life
sciences company developing innovative, targeted cancer treatments
and powerful diagnostics, today announces that the company will
present updated data from the Phase 1a
trial of AVA6000 at the 2024 European
Society for Medical Oncology (ESMO) Congress, in Barcelona, Spain
from 13-17 September 2024.
The poster presentation will be
based on an updated data cut from the Phase
1a trial of AVA6000 in patients with
Fibroblast Activation Protein (FAP)-positive solid tumours.
AVA6000 is a peptide drug conjugate
consisting of doxorubicin conjugated with a peptide moiety that is
specifically cleaved by FAP in the tumour
microenvironment.
Abstract details are listed below and
available online on the ESMO website.
Title: A Phase I trial of
AVA6000, a Fibroblast Activation Protein (FAP)-released, tumour
microenvironment (TME)-targeted doxorubicin peptide drug conjugate
in patients with FAP-positive solid tumours
Session Title: Developmental
therapeutics
Session Date and Time: Saturday, September 14, 2024, 9AM CEST time.
Location: Fira Barcelona Gran
Via Av. Joan Carles, Barcelona, Spain
Abstract Presentation Number: 646P
First Author: Professor Chris
Twelves, University of Leeds
-Ends-
For
further information from Avacta Group plc, please
contact:
|
Avacta Group plc
Christina Coughlin, CEO
Michael Vinegrad, Group
Communications
Director
|
Tel: +44 (0) 1904 21 7070
www.avacta.com
|
|
|
|
|
Peel Hunt (Nomad and Broker)
James Steel / Chris Golden / Patrick
Birkholm
|
www.peelhunt.com
|
|
ICR
Consilium
Mary-Jane Elliott / Jessica Hodgson
/ Sukaina Virji
|
avacta@consilium-comms.com
|
About Avacta Group plc - www.avacta.com
Avacta Group is a UK-based life
sciences company focused on improving healthcare outcomes through
targeted cancer treatments and diagnostics.
Avacta Therapeutics: a clinical
stage oncology biotech division harnessing proprietary therapeutic
platforms to develop novel, highly targeted cancer
drugs.
Avacta Diagnostics focuses on
supporting healthcare professionals and broadening access to
diagnostics.
Avacta has two proprietary
platforms, pre|CISION™ and Affimer®.
The pre|CISION™ platform is a highly
specific substrate for fibroblast activation protein (FAP) which is
upregulated in most solid tumours compared with healthy tissues.
The pre|CISION™ platform harnesses this tumour specific protease to
activate pre|CISION™ peptide drug conjugates and pre|CISION™
antibody/Affimer® drug conjugates in the tumour microenvironment,
reducing systemic exposure and toxicity, allowing dosing to be
optimised to deliver the best outcomes for patients.
The lead pre|CISION™ programme
AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase
1 studies. It has shown an improvement in safety and tolerability
in clinical trials to date compared with standard doxorubicin and
preliminary signs of clinical activity in multiple
patients.
To register for news alerts by email
go to www.avacta.com/investor-news-email-alerts